| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000033843 |
| Receipt No. | R000038598 |
| Scientific Title | A study to investigate the Serum uric acid level drop effect of ingesting test beverage for adult male with serum uric acid level above 7.1 mg/dL-under7.9 mg/dL |
| Date of disclosure of the study information | 2018/08/24 |
| Last modified on | 2019/09/25 (Ver. 5) |
| Basic information | ||
| Public title | A study to investigate the Serum uric acid level drop effect of ingesting test beverage for adult male with serum uric acid level above 7.1 mg/dL-under7.9 mg/dL | |
| Acronym | A study to investigate the Serum uric acid level drop effect of ingesting test beverage for adult male with serum uric acid level above 7.1 mg/dL-under7.9 mg/dL | |
| Scientific Title | A study to investigate the Serum uric acid level drop effect of ingesting test beverage for adult male with serum uric acid level above 7.1 mg/dL-under7.9 mg/dL | |
| Scientific Title:Acronym | A study to investigate the Serum uric acid level drop effect of ingesting test beverage for adult male with serum uric acid level above 7.1 mg/dL-under7.9 mg/dL | |
| Region |
|
|
| Condition | |||
| Condition | None | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The aim of this study is to obtain evidence in the Serum uric acid level change in 4 consecutive weeks ingesting test beverage (beverage being testing) for adult male with serum uric acid level above 7.1 mg/dL-under7.9 mg/dL by comparing to the control beverage |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Serum uric acid level and it's change |
| Key secondary outcomes | Urine creatinine, uric acid in the urine and it's change
Urinary uric acid excretion, Uric acid clearance, Creatinine clearance, Uric acid excretion rate and it's change |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of test beverage (4 weeks). | |
| Interventions/Control_2 | Ingestion of control beverage (4 weeks). | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1) 20 years of age or older male
2) Subjects with serum uric acid level above 7.1 mg/dL-under7.9 mg/dL at screening 3) Subjects who competent to consent and give voluntary consent in writing with full understanding after receiving explanation of this study aim and contents. |
|||
| Key exclusion criteria | 1) Subjects who are under drug treatment for hyperuricemia or gout, or subjects who are provided lifestyle guidance by medical doctor
2) Subjects who have history of gout 3) Subject who intake dairy product that is effective in lowering serum uric acid level on a daily basis 4) Subjects who in take health food that is effective in lowering serum uric acid level on daily basis 5) Subjects who exercise vigorously 6) Subjects with urinary tract infection, hepatic disorder, cardiac disorder, urinary tract stone disease, kidney disturbance, hypertension, diabetes, or subjects who have history of medication for those diseases, or subjects who are going to have medication during the study 7) Subjects with daily energy intake of over 4,000 kcal on Food Frequency Questionnaire Based on Food Group, FFQg, at the background investigation 8) Subjects with allergy to milk or soy 9) Subjects who had participated in other clinical trials within 1 month 10) Any candidates considered to be unsuitable for enrollment in the opinion of the principal investigator or investigator |
|||
| Target sample size | 106 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medical Corporation Chisei-kai Tokyo Center Clinic | ||||||
| Division name | Medical Corporation Chisei-kai Tokyo Center Clinic | ||||||
| Zip code | 1030028 | ||||||
| Address | Yaesu KT Bldg 1-1-8 Yaesu, Chuo-ku, Tokyo | ||||||
| TEL | 07033513779 | ||||||
| nakano_satomi@tc-clinic.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Tokyo Center Clinic | ||||||
| Division name | Clinical Research Center | ||||||
| Zip code | 1030028 | ||||||
| Address | 2F YS Build. 1-13-23 Minamiikebukuro Toshima-ku, Tokyo, Japan | ||||||
| TEL | 07033513779 | ||||||
| Homepage URL | |||||||
| nakano_satomi@tc-clinic.jp | |||||||
| Sponsor | |
| Institute | 3H Medi Solution Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Meiji Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Japan Conference of Clinical Research |
| Address | 28F YS Build. 1-13-23 Minamiikebukuro Toshima-ku, Tokyo, Japan |
| Tel | 03-6868-7022 |
| jccr-info@cts-smo.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東京センタークリニック(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 71 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038598 |